The in vitro antifungal activity and spectrum of FK463 were compared with those of amphotericin B, fluconazole, and itraconazole by using a broth microdilution method specified by National Committee for Clinical Laboratory Standards document M27-A (National Committee for Clinical Laboratory Standards, Wayne, Pa., 1997). FK463 exhibited broad-spectrum activity against clinically important pathogens including Candida species (MIC range, Ϲ0.0039 to 2 g/ml) and Aspergillus species (MIC range, Ϲ0.0039 to 0.0313 g/ml), and its MICs for such fungi were lower than those of the other antifungal agents tested. FK463 was also potently active against azole-resistant Candida albicans as well as azole-susceptible strains, and there was no cross-resistance with azoles. FK463 showed fungicidal activity against C. albicans, i.e., a 99% reduction in viability after a 24-h exposure at concentrations above 0.0156 g/ml. The minimum fungicidal concentration (MFC) assays indicated that FK463 was fungicidal against most isolates of Candida species. In contrast, the MFCs of FK463 for A. fumigatus isolates were much higher than the MICs, indicating that its action is fungistatic against this species. FK463 had no activity against Cryptococcus neoformans, Trichosporon species, or Fusarium solani. Neither the test medium (kind and pH) nor the inoculum size greatly affected the MICs of FK463, while the addition of 4% human serum albumin increased the MICs for Candida species and A. fumigatus more than 32 times. Results from preclinical in vitro evaluations performed thus far indicate that FK463 should be a potent parenteral antifungal agent.
The currently available antifungal drugs for the treatment of deep-seated mycoses are limited to amphotericin B (AMPH-B), azole compounds, and flucytosine. AMPH-B remains the drug of choice for the treatment of most fungal diseases because it has broad-spectrum and potent fungicidal activity, but it is well known to be toxic (16) . Although the azole antifungal agents are considered to be less toxic than AMPH-B, their efficacies against deep-seated, life-threatening mycoses are not satisfactory. In addition, it has been reported that the frequency of isolation of multiazole-resistant strains of Candida species other than Candida albicans is increasing (6) . Therefore, there is a critical need for new antifungal agents which are fungicidal, have a broad spectrum of activity and have fewer side effects. Inhibition of glucan synthesis is an attractive target for antifungal agents, since the absence of homologous enzymes in humans may afford a high degree of selectivity for fungi (5) . Moreover, an inhibitor of glucan synthesis could possess activity against fungi resistant to other antifungal agents (7, 17, 19) . These considerations have led to the development of the echinocandin LY303366 by Eli Lilly & Company and the related pneumocandin MK-0991 by Merck Research Laboratories. Both of these compounds have been introduced into clinical trials (2, 14) . The MICs of these compounds for various yeast isolates were determined in accordance with the standard reference method, recently developed by consensus through the National Committee for Clinical Laboratory Standards (9, 12) . The guidelines for antifungal susceptibility testing of yeasts were applied to in vitro susceptibility testing of various filamentous fungi (8, 13, 15, 19) . Under standard conditions, both LY303366 and MK-0991 displayed substantial activities against Candida and Aspergillus species.
FK463 is a semisynthetic derivative of FR901379, a watersoluble echinocandin-like lipopeptide with a sulfonate moiety, isolated from the culture broth of Coleophoma empedri (T. Iwamoto, N. Sakamoto, M. Yamashita, M. Ezaki, S. Hashimoto, T. Furuta, M. Okuhara, and M. Kohsaka, Program Abstr. 33rd Intersci. Conf. Antimicrob. Agents Chemother., abstr. 371, 1993). In order to define clearly the in vitro antifungal activity of FK463, we determined the susceptibilities of several clinically important pathogenic fungi under the conditions mentioned above.
termine the MICs of FK463 and other reference antifungal agents. RPMI 1640 medium with L-glutamine and without sodium bicarbonate was buffered with 165 mM morpholinepropanesulfonic acid (MOPS) buffer (pH 7.0) and was used as a test medium. All test compounds except ITCZ were solubilized in distilled water at 1,280 g/ml. ITCZ was solubilized in dimethyl sulfoxide at 1,280 g/ml. The compounds were then diluted to 64 g/ml in RPMI 1640 medium and were serially diluted twofold, yielding final drug concentrations ranging from 64 to 0.0078 g/ml. Inoculum suspensions of 10 6 cells/ml were prepared by a hemocytometric procedure and were diluted to obtain an inoculum size of approximately 1.0 ϫ 10 3 to 2.5 ϫ 10 3 cells/ml. Microplates were incubated at 35°C for Candida species, Saccharomyces cerevisiae, Cryptococcus neoformans, Aspergillus species, and Trichosporon species and at 30°C for Fusarium solani; and readings were taken when good growth in the growth control well was observed. The MICs of FK463 and AMPH-B for yeasts were defined as the lowest concentrations at which no visible growth was observed, and the MICs of FLCZ and ITCZ were defined as the lowest concentrations at which a prominent decrease in turbidity was observed. The MICs of all the compounds tested for filamentous fungi were defined as the lowest concentrations at which a prominent decrease in turbidity compared with that for the growth control was observed.
Influence of experimental conditions on MIC. The influences of medium, initial pH, inoculum size, and the addition of human serum albumin (HSA) on MICs were determined analogously by the broth microdilution method with RPMI 1640 medium, yeast nitrogen base-dextrose (YNBD) medium, Sabouraud dextrose (SD) medium, or PYG (0.5% yeast extract-containing SD) medium as a test medium, a pH range of 5 to 8, cell concentrations of 10 2 to 10 5 CFU/ml, and HSA concentrations of 0 to 4%.
Fungicidal activity. A culture of C. albicans FP633 was diluted with RPMI 1640 medium buffered with 165 mM MOPS buffer (pH 7.0) to a concentration of 10 4 CFU/ml. After preincubation for 1 h at 35°C, the antifungal agents were added at various concentrations. The number of viable organisms was determined at 24 h after the addition of drugs by plate counts. MFC assays. After the MIC was measured, the microtiter plates were shaken and a 100-l sample from each well of the microtiter plate was transferred to a single-reservoir plate containing SD agar, and these plates were incubated for more than 72 h at 35°C. The minimum fungicidal concentration (MFC) was defined as the minimum concentration of compound which resulted in the growth of less than 2 CFU. This represents killing of Ͼ99% of the original inoculum.
RESULTS
Antifungal spectrum. Table 1 shows the spectrum of activity of FK463 and other reference antifungal agents against various yeasts and molds. FK463 had a broad-spectrum and potent activity against a variety of fungal species. FK463 was more active than AMPH-B, FLCZ, and ITCZ against most Candida species and all Aspergillus species tested. However, FK463 was inactive against C. neoformans, Trichosporon cutaneum, Trichosporon asahii, and F. solani.
MICs for clinical isolates of fungi. Table 2 shows the MICs of FK463 and other antifungal agents for clinical isolates of yeast. The FK463 MICs at which 90% of isolates are inhibited (MIC 90 s) for C. albicans, including FLCZ-resistant strains, Candida tropicalis, Candida glabrata, and Candida krusei were 0.125 g/ml or lower; and FK463 was more potent than the other antifungal agents tested. Against Candida parapsilosis and Candida guilliermondii isolates, the MIC 90 s of FK463 were 1 and 2 g/ml, respectively, which was slightly less than those of ITCZ and AMPH-B. FK463 had no activity in vitro against C. neoformans and T. cutaneum isolates. Table 3 shows the MICs of FK463 for clinical isolates of Aspergillus species. The MIC 90 s of FK463 for the four species of Aspergillus were 0.0078 to 0.0156 g/ml, and its MICs were lower than those of the other antifungal agents tested.
Fungicidal activity. Figure 2 shows the relationship between the change in viable cell counts and drug concentration when C. albicans FP633 was exposed to FK463 and other antifungal agents for 24 h. A 99% or more reduction in viability was observed after 24 h of exposure to FK463 at concentrations above 0.0156 g/ml. FK463 exhibited fungicidal activity at con- centrations lower than those at which AMPH-B exhibited fungicidal activity, and its activity was superior to those of FLCZ and ITCZ, which had only fungistatic activities.
MFCs for clinical isolates of Candida species and Aspergillus fumigatus. Table 4 shows the MFCs (killing of Ͼ99% of the original inoculum) of FK463 and other antifungal agents for clinical isolates of six Candida species (including FLCZ-resistant C. albicans) and A. fumigatus. The FK463 MFCs at which 90% of isolates are inhibited (MFC 90 s) for C. albicans, including FLCZ-resistant strains, C. glabrata, and C. krusei were 0.5 g/ml or lower; and FK463 was more potent than the other antifungal agents tested. Against C. tropicalis, C. parapsilosis, and C. guilliermondii isolates, the MFC 90 s of FK463 were Ͼ64, 8, and Ͼ64 g/ml, respectively, which were less than those of AMPH-B. The MFCs of FK463 for A. fumigatus isolates were much higher than the MICs, indicating that its action is fungistatic against this species.
Influence of experimental conditions on activity of FK463. Table 5 shows the influence of the kind and pH of the medium, inoculum size, and addition of HSA on the MIC of FK463. The kind and initial pH of the medium and inoculum size did not significantly affect the MIC of FK463 for C. albicans, C. glabrata, and A. fumigatus. In contrast, the addition of 4% HSA increased the MICs for these strains more than 32 times.
DISCUSSION
FK463 is a semisynthetic derivative of FR901379, which is a water-soluble echinocandin-like lipopeptide isolated from the culture broth of C. empedri (Iwamoto et al., 33rd ICAAC). FR901379 and related compounds were shown to have inhibitory activities on 1,3-␤-D-glucan synthase (Iwamoto et al., 33rd ICAAC), and these activities were similar to those of echinocandin B analogs and the pneumocandins (4, 5, 10) . In this a MICs were determined by the microdilution method described in National Committee for Clinical Laboratory Standards document M27-A (12). The methods used to determine the MICs for the yeasts are described in the text. Unless otherwise noted, incubation was for 24 to 48 h at 35°C. a Microtiter plates were shaken and 0.1-ml samples were transferred to SD agar plates, which were incubated for more than 72 hours at 35°C.
of the compound to the target may be related to relative resistance, as pointed out by Bartizal et al. (3) .
In conclusion, these results suggest that FK463 is a promising compound for further evaluation as a new antifungal candidate. a Broth microdilution testing was used. The MICs for Candida species were determined as the minimum concentration resulting in at least 80% inhibition of growth of Candida species measured as a decrease in turbidity compared with the turbidities of the growth controls. The MICs for A. fumigatus were determined as the minimum concentration resulting in a prominent decrease in turbidity compared with the turbidity of the growth control.
b Incubation was for 48 h at 35°C. c Incubation was for 72 h at 35°C.
